EP4025609A4 - ANTI-STEAP1 ANTIBODIES AND THEIR USES - Google Patents

ANTI-STEAP1 ANTIBODIES AND THEIR USES Download PDF

Info

Publication number
EP4025609A4
EP4025609A4 EP20860238.3A EP20860238A EP4025609A4 EP 4025609 A4 EP4025609 A4 EP 4025609A4 EP 20860238 A EP20860238 A EP 20860238A EP 4025609 A4 EP4025609 A4 EP 4025609A4
Authority
EP
European Patent Office
Prior art keywords
steap1
antibodies
steap1 antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20860238.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4025609A1 (en
Inventor
Nai-Kong V. Cheung
Tsung-Yi Lin
Steven M. Larson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP4025609A1 publication Critical patent/EP4025609A1/en
Publication of EP4025609A4 publication Critical patent/EP4025609A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
EP20860238.3A 2019-09-05 2020-09-04 ANTI-STEAP1 ANTIBODIES AND THEIR USES Pending EP4025609A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962896415P 2019-09-05 2019-09-05
PCT/US2020/049377 WO2021046331A1 (en) 2019-09-05 2020-09-04 Anti-steap1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EP4025609A1 EP4025609A1 (en) 2022-07-13
EP4025609A4 true EP4025609A4 (en) 2023-10-04

Family

ID=74853055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20860238.3A Pending EP4025609A4 (en) 2019-09-05 2020-09-04 ANTI-STEAP1 ANTIBODIES AND THEIR USES

Country Status (9)

Country Link
US (1) US20220348686A1 (https=)
EP (1) EP4025609A4 (https=)
JP (1) JP7805287B2 (https=)
KR (1) KR20220057575A (https=)
CN (1) CN114929743B (https=)
AU (1) AU2020343652A1 (https=)
CA (1) CA3150149A1 (https=)
IL (1) IL291027A (https=)
WO (1) WO2021046331A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240415888A1 (en) * 2021-10-20 2024-12-19 Memorial Sloan Kettering Cancer Center Anti-tshr multi-specific antibodies and uses thereof
GB202208119D0 (en) * 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car
CA3261989A1 (en) * 2022-07-22 2024-01-25 Genentech, Inc. ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND THEIR USES
US20260042860A1 (en) * 2022-08-04 2026-02-12 Memorial Sloan-Kettering Cancer Center Anti-cd24 antibodies and uses thereof
AU2024243972A1 (en) * 2023-04-06 2025-10-23 Memorial Hospital For Cancer And Allied Diseases Il-10 receptor antibodies and methods of use thereof
WO2025042872A1 (en) * 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Combination therapy for treating prostate cancer
WO2025042865A1 (en) * 2023-08-21 2025-02-27 Amgen Research (Munich) Gmbh Methods for treating prostate cancer with bispecific antibodies binding steap1xcd3
WO2025128807A1 (en) * 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
CN119113151B (zh) * 2024-08-01 2025-11-18 华中科技大学同济医学院附属同济医院 一种前列腺癌特异性细胞外囊泡荧光探针及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113601A2 (en) * 2004-04-22 2005-12-01 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2008052187A2 (en) * 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
WO2017055388A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573384B (zh) * 2006-10-27 2013-02-20 健泰科生物技术公司 抗体和免疫偶联物及其用途
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
RU2613886C2 (ru) * 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
BR112014012882A2 (pt) * 2011-11-29 2017-06-13 Genentech Inc método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
KR101911438B1 (ko) * 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
US20170043034A1 (en) * 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
MX2017003123A (es) * 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
CN113552350B (zh) * 2015-04-21 2024-10-11 基因泰克公司 用于前列腺癌分析的组合物和方法
KR20180023949A (ko) * 2015-06-09 2018-03-07 메모리얼 슬로안-케터링 캔서 센터 인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
SG11201909218RA (en) * 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
US12084514B2 (en) * 2017-12-04 2024-09-10 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
EP3938400B1 (en) * 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113601A2 (en) * 2004-04-22 2005-12-01 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2008052187A2 (en) * 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
WO2017055388A2 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHALLITA-EID PIA M ET AL: "Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 67, no. 12, 15 June 2007 (2007-06-15), pages 5798 - 5805, XP002469628, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-06-3849 *
ESMAEILI SEYED-ALIREZA ET AL: "Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 18, no. 12, 1 January 2018 (2018-01-01), pages 1674 - 1679, XP009516077, ISSN: 1875-5992, DOI: 10.2174/1871520618666171208092115 *
See also references of WO2021046331A1 *

Also Published As

Publication number Publication date
CA3150149A1 (en) 2021-03-11
JP7805287B2 (ja) 2026-01-23
WO2021046331A1 (en) 2021-03-11
IL291027A (en) 2022-05-01
CN114929743A (zh) 2022-08-19
AU2020343652A1 (en) 2022-03-24
US20220348686A1 (en) 2022-11-03
CN114929743B (zh) 2026-01-02
KR20220057575A (ko) 2022-05-09
JP2022546572A (ja) 2022-11-04
EP4025609A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
IL289354A (en) Anti-cd154 antibodies and uses thereof
EP4085076C0 (en) BCMA-BINDING ANTIBODIES AND THEIR USES
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND ITS USES
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND ITS USES
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
EP3621642C0 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES
EP4025609A4 (en) ANTI-STEAP1 ANTIBODIES AND THEIR USES
EP3571231A4 (en) ANTI-PD-1 ANTIBODIES AND THEIR USES
EP3592386A4 (en) ANTI-C5 ANTIBODIES AND THEIR USES
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP4359442A4 (en) ANTI-CCR8 ANTIBODIES AND THEIR USES
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
EP3672987C0 (en) ANTI-APELIN ANTIBODIES AND THEIR USES
EP3630825A4 (en) INTERLEUKIN-2 ANTI-HUMAN ANTIBODIES AND THEIR USES
EP4142793A4 (en) ABCB5-SPECIFIC ANTIBODIES AND THEIR USES
EP4126938A4 (en) ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
EP3621993A4 (en) ANTI-INTERFERON GAMMA ANTIBODIES AND THEIR USES
EP4244255A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP4132569A4 (en) ANTI-PHF-TAU ANTIBODIES AND USES
EP3585800A4 (en) Novel minor histocompatibility antigens and uses thereof
EP4247419A4 (en) ANTI-MARCO ANTIBODIES AND RELATED USES
IL291550A (en) Anti-il-27 antibodies and uses thereof
EP4076526A4 (en) Novel ddr1 antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230904

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230829BHEP

Ipc: C07K 16/40 20060101ALI20230829BHEP

Ipc: C07K 16/32 20060101ALI20230829BHEP

Ipc: C07K 16/30 20060101ALI20230829BHEP

Ipc: C07K 16/28 20060101AFI20230829BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251027